Coloplast A/S/DKr COLO B
1D1W1MYTD1Y5YMAX
Capital at risk
About Coloplast A/S
Coloplast A/S is a Danish company specializing in the development and manufacturing of medical devices and services. Its core business operates within the healthcare industry, focusing on products for ostomy care, continence care, wound and skin care, and urology. Founded in 1957, the company has a significant history of innovation in personalized healthcare products. Headquartered in Humlebæk, Denmark, Coloplast serves a global market, ensuring strong geographic diversification. The company is strategically positioned with strengths in customer-centric product development and a robust distribution network, enhancing its competitive advantage in the medical devices sector.
- Ticker
- DKr COLO B
- Sector
- Health
- Primary listing
- CSE
- Employees
- 17,213
- Headquarters
- Humlebæk, Denmark
- Website
- www.coloplast.com
Coloplast A/S Metrics
BasicAdvanced
kr 94B
34.18
kr 12.26
0.55
kr 23.00
5.49%
Price and volume
Market cap
kr 94B
Beta
0.55
52-week high
kr 631.40
52-week low
kr 369.70
Average daily volume
324K
Dividend rate
kr 23.00
Financial strength
Current ratio
1.561
Quick ratio
0.883
Long term debt to equity
156.535
Total debt to equity
178.073
Dividend payout ratio (TTM)
187.59%
Interest coverage (TTM)
11.52%
Profitability
EBITDA (TTM)
8,625
Gross margin (TTM)
67.23%
Net profit margin (TTM)
9.71%
Operating margin (TTM)
26.98%
Effective tax rate (TTM)
30.51%
Revenue per employee (TTM)
kr 1,650,000
Management effectiveness
Return on assets (TTM)
10.12%
Return on equity (TTM)
18.53%
Valuation
Price to earnings (TTM)
34.182
Price to revenue (TTM)
3.319
Price to book
7.01
Price to tangible book (TTM)
-6.71
Price to free cash flow (TTM)
15.415
Free cash flow yield (TTM)
6.49%
Free cash flow per share (TTM)
27.188
Dividend yield (TTM)
5.49%
Growth
Revenue change (TTM)
2.06%
Earnings per share change (TTM)
-32.17%
3-year revenue growth (CAGR)
5.34%
10-year revenue growth (CAGR)
6.92%
3-year earnings per share growth (CAGR)
-18.35%
10-year earnings per share growth (CAGR)
7.26%
3-year dividend per share growth (CAGR)
4.77%
10-year dividend per share growth (CAGR)
11.14%
Bulls say / Bears say
Coloplast delivered 6% organic revenue growth and 6% EBIT growth in constant currencies in Q2 of H1 2025/26, achieving a 15% return on invested capital after tax before special items, underscoring robust operational performance despite currency headwinds. (Reuters)
Coloplast secured an innovative technology contract with Vizient for its Biatain® Silicone Fit dressing, strengthening its U.S. distribution network and enhancing its wound‐care product penetration. (Reuters)
Coloplast appointed Gavin Wood, former Johnson & Johnson MedTech EMEA Company Group Chairman with two decades of leadership experience, as CEO effective May 1, 2026, reinforcing strategic direction under seasoned management. (Coloplast Press Release)(Reuters)
Coloplast recognised a DKK 3.0 billion impairment loss against the goodwill of its Kerecis acquisition in H1 2025/26, signalling integration setbacks and reducing the carrying value of its wound‐care unit. (Reuters)
Changes to U.S. Medicare reimbursement led Coloplast’s Kerecis outpatient business to “basically collapse,” driving Biologics sales down 6% in Q3 and producing a –5% EBIT margin, with management forecasting negative growth through Q4 2026. (Reuters)
Reported H1 revenue grew just 2% with a 4-percentage-point drag from foreign‐exchange movements, while roughly 70 basis points of EBIT margin were lost to currency headwinds, highlighting significant forex exposure. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 24 Aug 2026.
Upcoming events
No upcoming events
Funds containing Coloplast A/S
AllEURGBPUSD
Fund name | Fund size | DKr COLO B weighting |
|---|---|---|
iShares STOXX Europe 600 Health Care€EXV4 | €687M | 0.57% |
iShares STOXX Europe Mid 200€EXSD | €610M | 0.56% |
iShares MSCI Europe Health Care Sector€ESIH | €863M | 0.44% |
iShares MSCI Europe Health Care Sector£ESIH | £741M | 0.44% |
iShares MSCI Europe SRI€IESE | €3.1B | 0.32% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.